Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

ChemoMetec

655.00 DKK+0.08 %4.11, 15.54
Less than 1K followers

CHEMM

NASDAQ Copenhagen

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.08 %
+18.98 %
+57.15 %
+100.92 %
-4.73 %
-17.04 %
+95.06 %
-36.84 %
+2,877.27 %

ChemoMetec specializes in the design, development, and production of patented instruments for cell counting and cell analysis. The company cooperates and statutes agreements with actors such as research institutes, universities, food companies, hospitals, and specialist clinics. Customers are found in a global market. The company was founded in 1997 and is headquartered in Alleröd, Denmark.

Read more
Market cap
11.4B DKK
Turnover
30.16M DKK
Revenue
511.06M
EBIT %
49.11 %
P/E
56.47
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
3.2
2027

Interim report Q2'27

9.9
2027

Annual report '27

All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release03.11.2026, 10.21

Opjustering af forventningerne til omsætning og driftsresultat

ChemoMetec
Regulatory press release03.11.2026, 10.21

Upgrade of revenue and operating profit guidance

ChemoMetec
Regulatory press release28.10.2026, 18.18

Major shareholder announcement - BlackRock, Inc.

ChemoMetec

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release28.10.2026, 18.18

Storaktionærmeddelelse - BlackRock, Inc.

ChemoMetec
Regulatory press release21.10.2026, 20.42

Major shareholder announcement - BlackRock, Inc.

ChemoMetec
Regulatory press release21.10.2026, 20.42

Storaktionærmeddelelse - BlackRock, Inc.

ChemoMetec
Press release19.10.2026, 13.16

ChemoMetec A/S afholder telefonkonference den 6. november 2026 kl. 15.00 til præsentation af kvartalsregnskabet for 1. kvartal 2026/27

ChemoMetec
Press release19.10.2026, 13.16

ChemoMetec A/S invites to conference call on November 6, 2026, at 3:00 PM CET to present Q1 2026/27 financial results

ChemoMetec
Regulatory press release08.10.2026, 22.33

Iværksættelse af aktietilbagekøbsprogram

ChemoMetec
Regulatory press release08.10.2026, 22.33

Initiation of buy-back programme

ChemoMetec
Regulatory press release08.10.2026, 19.57

Procedure of the Annual General Meeting

ChemoMetec
Regulatory press release08.10.2026, 19.57

Forløb af ordinær generalforsamling

ChemoMetec
HCA Morgenbørs 06/10 - Fokus på JDC Group i interview med CEO Andreas Aaen fra Symmetry Invest
Video06.10.2026, 09.31
by Michael Friis, Jacob Frehr

HCA Morgenbørs 06/10 - Fokus på JDC Group i interview med CEO Andreas Aaen fra Symmetry Invest

Udsigt til en svag positiv åbning i Europa fra morgenstunden efter rekord i Nasdaq. Fokus på Genmab (data i lymfekræft) og TORM (Oaktree sælger ud). Gæst i studiet her til morgen er CEO Andreas Aaen fra Symmetry Invest, der bl.a. vil tale om JDC Group.

Danske BankCarlsbergGenmabColoplastGabriel HoldingChemoMetecTormHafnia
Regulatory press release05.10.2026, 21.52

Major shareholder announcement - BlackRock, Inc.

ChemoMetec
Regulatory press release05.10.2026, 21.52

Storaktionærmeddelelse - BlackRock, Inc.

ChemoMetec
Regulatory press release05.10.2026, 10.48

Opjustering af omsætning og driftsresultat

ChemoMetec
Regulatory press release05.10.2026, 10.48

Upgrade of revenue and operating profit guidance

ChemoMetec
Regulatory press release02.10.2026, 16.52

Completion of share buyback programme

ChemoMetec
Regulatory press release02.10.2026, 16.52

Afslutning af aktietilbagekøbsprogram

ChemoMetec
Regulatory press release16.09.2026, 14.37

Major shareholder announcement - BlackRock, Inc.

ChemoMetec